Relationship of NaPi2b expression and efficacy of XMT-1536, a NaPi2b targeting antibody-drug conjugate (ADC), in an unselected panel of human primary ovarian mouse xenograft models

被引：4
|
作者：
Mosher, Rebecca [1 ]
Poling, Laura [1 ]
Qin, LiuLiang [1 ]
Bodyak, Natalya [1 ]
Bergstrom, Donald [1 ]
机构：
[1] MersanaTherapeutics, Cambridge, MA USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-B119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B119
引用
收藏
页数：2
相关论文
共 34 条
  • [31] A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
    Banerjee, Susana N.
    Oza, Amit M.
    Birrer, Michael J.
    Hamilton, Erika Paige
    Hasan, Jurjees
    Leary, Alexandra
    Moore, Kathleen N.
    Mackowiak-Matejczyk, Beata
    Pikiel, Joanna
    Ray-Coquard, Isabelle
    Trask, Peter
    Lin, Kedan
    Vaze, Anjali
    Choi, YounJeong
    Marsters, Jim
    Maslyar, Daniel J.
    Lemahieu, Vanessa
    Wang, Yulei
    Humke, Eric William
    Liu, Joyce F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] UP-NEXT (GOG-3049/ENGOT-OV71-NSGO-CTU): A STUDY OF UPIFITAMAB RILSODOTIN (UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER
    Richardson, Debra
    Harter, Philipp
    O'Malley, David
    Gonzalez-Martin, Antonio
    Herzog, Thomas
    Rogalski, Caroline
    Burger, Robert
    Mirza, Mansoor
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
  • [33] UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer
    Richardson, Debra L.
    Harter, Philipp
    O'Malley, David M.
    Martin, Antonio Gonzalez
    Herzog, Thomas J.
    Rogalski, Caroline
    Lemming, Rita
    Keeton, Erika
    Burger, Robert Allen
    Mirza, Mansoor Raza
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non- small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).
    Gordon, Michael S.
    Gerber, David E.
    Infante, Jeffrey R.
    Xu, Jian
    Shames, David S.
    Choi, Younjeong
    Kahn, Robert S.
    Lin, Kedan
    Wood, Katie
    Maslyar, Daniel J.
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
1234